Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

Prostate Cancer Clinical Trial

— PROSTEP-002  

Official title:

Detection and Monitoring of Metastasis by 18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer and Negative, Equivocal, or Oligometastatic Disease on Conventional Imaging (PROSTEP-002)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04655365
• Other study ID #: PROSTEP-002
• Status: Recruiting
• Phase: Phase 2
• Start date: March 22, 2022
• Est. completion date: June 1, 2025

Study information

• Verified date: February 2024
• Source: CHU de Quebec-Universite Laval
• Contact: Marie-Christine Dubé, PhD
• Phone: 418 525-4444
• Email: marie-christine.dube[@]crchudequebec.ulaval.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aimed to evaluate the diagnostic performance of 18F-DCFPyL (PyL) PET/CT in subjects presenting not previously treated for castration resistant prostate cancer and showing negative or equivocal findings per institutional standard of care conventional imaging

Description:

Prostate cancer (PCa) is the most common solid organ cancer in North American men and is initially androgen sensitive. Therefore, castration and/or androgen receptor blockade remains the central palliative treatment once PCa has metastasized or failed to locoregional therapies. Because androgen deprivation therapy is not curative, all patients will eventually progress to the metastatic castration-resistant prostate cancer state. About 5% of prostate cancers will be metastatic by conventional imaging techniques at diagnosis while most patients achieving CRPC state will first be localized and then progress to metastatic state later in the disease course. Therefore, a significant proportion of patients will progress through an intermediary state of disease defined as the non-metastatic CRPC state (M0CRPC). Over the last year and a half, M0CRPC treatment landscape has completely changed with demonstrating the benefits of second-generation antiandrogens (darolutamide, enzalutamide and apalutamide) to prevent progression of M0CRPC patients. Enzalutamide have then been approved by the Federal Drug Administration and Health Canada for the treatment of M0CRPC. On the other hand, conventional imaging techniques based on bone turnover (bone scan (BS)) or anatomical features (magnetic resonance imaging (MRI) or computed tomography (CT)) have important limitations and poor accuracy. Bone scans (BS) is the commonest imaging technique used to detect bone metastases in the clinics. BS does not image directly cancer cells, but the effect of cancer on the bone. Other pathologies such as fractures, degenerative arthritis and other benign bone lesions can also cause focal uptake on BS and lead to false-positive results. Another drawback of BS is its poor sensitivity to image small metastases confined to bone marrow. These limitations stress the importance to improve PCa imaging by using new imaging modalities. Because novel agents targeting the androgen synthesis and receptor axis (e.g. enzalutamide), bone metastasis (radium-223) and microtubules assembly (docetaxel, cabazitaxel) have been shown to increase metastatic CRPC patients overall survival, a burning question is to determine if the non-metastatic CRPC status is real. There is growing evidence that newer imaging techniques using positron emission tomography can improve metastasis detection accuracy and may refine PCa patient prognostic stratification and treatment eligibility.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: June 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed adenocarcinoma of the prostate per original diagnosis, with undergoing androgen deprivation therapy such as prior bilateral orchiectomy or surgical castration or LHRH-agonists/LHRH-antagonists.
• Suspected recurrence of prostate cancer based on rising PSA under androgen deprivation therapy. Recurrent castration resistant prostate cancer patients are defined by a rising PSA >1 ng/mL under ADT or surgical castration and with testosterone castration levels < 1.7 nM (PCWG3 criteria).
• Negative, equivocal findings or oligometastatic disease (< 5) for prostate cancer on conventional imaging bone scan AND 2) abdomen-pelvis CT/MRI and chest CT or FDG-PET/CT or 18F-NaF PET/CT performed as standard of care workup within 90 days of signing the ICF.
• The subject is candidate for second line androgen axis targeted inhibitors such as enzalutamide and planned to receive it.
• Life expectancy =6 months as determined by the investigator
• Able and willing to provide signed informed consent and comply with protocol requirement
• PSA doubling time less or equal to 10 months
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.
• Able to swallow the study drug and comply with study requirements.

Exclusion Criteria:

• Subjects administered any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to study drug injection.
• Receipt of investigational drug therapy for prostate cancer within 60 days of Day 1.
• Known or suspected brain metastasis or active leptomeningeal disease.
• Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone acetate, or enzalutamide for prostate cancer.
• History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma). History of loss of consciousness (unless of cardiac origin) or transient ischemic attack within 12 months before enrollment.
• Major surgery within 4 weeks before randomization date.
• Absolute neutrophil count < 1000/µL, platelet count < 100,000/µL, or hemoglobin < 10 g/dL (6.2 mmol/L) at screening.
• Total bilirubin = 1.5-times the upper limit of normal or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2.5-times the upper limit of normal at screening.
• Creatinine > 2 mg/dL (177 µmol/L) at screening.
• Albumin < 3.0 g/dL (30 g/L) at screening.
• Clinically significant cardiovascular disease
• Gastrointestinal disorder affecting absorption.
• Ongoing drug or alcohol abuse as per investigator judgment.
• Subject has received any investigational radioactive agent within 28 days or 5 half-lives, whichever is longer, prior to screening.
• Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completing the study.
• Contraindication to enzalutamide
• Treatment with specific (5-a reductase inhibitors, estrogens, cyproterone actetate, biologic agents with antitumor activity, systemic glucocorticoids, androgens, ...) within 4 weeks of day 1 and during the study treatment period

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Enzalutamide capsule
160 mg po id

Locations

Country	Name	City	State
Canada	CHU de Québec-Université Laval	Québec

Sponsors (2)

Lead Sponsor	Collaborator
CHU de Quebec-Universite Laval	Astellas Pharma Europe Ltd.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number and sites of new lesions detected by 18F-DCFPyL-PSMA PET/CT at several PSA thresholds	Number of metastasis per compartment (bone, visceral, lymph node) determined by 18F-DCFPyL-PET/CT when PSA is <1 ng/mL, 1 to 5 ng/mL and > 5 ng/mL.	At the end of study completion, an average of 2 years
Other	Determine the percentage of patients showing metastatic lesions with enough 18F-DCFPyL uptake (above that of the liver) to justify radioligand therapy before and 3 months after enzalutamide treatment.	Analyze if a patient shows one or several lesions with a 18F-DCFPyL uptake more than that of the liver.	At the end of study completion, an average of 2 years
Primary	Determine the percentage of patients presenting new metastatic lesions detected by 18F-DCFPyL-PSMA PET/CT in castration resistant prostate cancer patients presenting non metastatic, equivocal or oligometastatic (< 5 metastasis) disease	Number of patients presenting with metastases per compartment (bone, visceral, lymph node) determined by 18F-DCFPyL-PSMA PET/CT that were negative or equivocal on conventional imaging. determined by 18F-DCFPyL-PET/CT.	At the end of study completion, an average of 2 years
Secondary	Determine the intrapatient and interpatient 18F-DCFPyL-PSMA response rates defined by a 50% decrease in intralesional 18F-DCFPyL-PSMA uptake or 50% decrease in sum metastasis 18F-DCFPyL-PSMA uptake after 3 months of enzalutamide.	Determine the changes in 18F-DCFPyL-PSMA sum metastasis SUVmax (or any other radiomic PET parameter) for each patient and the changes of 18F-DCFPyL-PSMA SUVmax (or any other radiomic PET parameter) in each lesion after 3 months of enzalutamide.	At the end of study completion, an average of 2 years